Metsera, Inc. Common Stock (NASDAQ:MTSR) — Market Cap & Net Worth
Market Cap & Net Worth: Metsera, Inc. Common Stock (MTSR)
Metsera, Inc. Common Stock (NASDAQ:MTSR) has a market capitalization of $4.12 Billion ($4.12 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4112 globally and #1405 in its home market, demonstrating a -13.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Metsera, Inc. Common Stock's stock price $70.50 by its total outstanding shares 105056000 (105.06 Million). Review MTSR liabilities breakdown to assess the company's total debt and financial obligations.
Metsera, Inc. Common Stock Market Cap History: 2025 to 2025
Metsera, Inc. Common Stock's market capitalization history from 2025 to 2025. Data shows growth from $7.41 Billion to $7.41 Billion (0.00% CAGR).
Index Memberships
Metsera, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.17% | #94 of 976 |
Weight: Metsera, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Metsera, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Metsera, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MTSR by Market Capitalization
Companies near Metsera, Inc. Common Stock in the global market cap rankings as of June 17, 2026.
Key companies related to Metsera, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Metsera, Inc. Common Stock Historical Marketcap From 2025 to 2025
Between 2025 and today, Metsera, Inc. Common Stock's market cap moved from $7.41 Billion to $ 7.41 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Metsera, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.12 Billion USD |
| MoneyControl | $4.12 Billion USD |
| MarketWatch | $4.12 Billion USD |
| marketcap.company | $4.12 Billion USD |
| Reuters | $4.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more